Philips Lumify Ultrasound Lawsuit | Injury & Death Investigation

The Philips Lumify ultrasound recall concerns software registration failures and unstable cable connections that may prevent healthcare professionals from obtaining diagnostic images during medical treatment.

On October 19, 2026, the FDA confirmed that the corrective action involving Philips Lumify was classified as a Class I recall.

A Class I recall is the FDA’s most serious recall classification and indicates that continued use of an affected product without appropriate precautions may cause serious injury or death.

The recall was initiated because Philips identified two problems affecting the Lumify diagnostic ultrasound system:

• Unexpected transducer re-registration: The Lumify app may fail to recognize a previously registered transducer and prompt users to complete registration again without warning prior to point-of-care use. This software issue prevents scanning functionality until re-registration is completed.
• Unstable USB connections: The connection between the Lumify transducer USB cable and a compatible Android device or iOS device may become unstable or disconnect, interrupting ultrasound imaging during a medical examination or procedure.

The software issue is particularly concerning because registration requires Wi-Fi or cellular signal access.

Although the Lumify system can perform normal scans without a continuous internet connection, unexpected re-registration events can lock clinicians out of the system until cellular access or Wi-Fi connectivity becomes available.

A Lumify transducer connected to a compatible Android device or Apple tablet may therefore become unusable during an emergency if the application unexpectedly demands re-registration.

Philips confirmed that these unexpected re-registration events have prevented scanning in pre-hospital environments and delayed patient care.

The manufacturer reported that the pre-hospital events occurred where Wi-Fi or cellular service was unavailable.

Lumify devices used in ambulances, helicopters, and remote settings may face a greater risk of delayed treatment because a reliable cellular signal or backup ultrasound device may not be immediately available.

The FDA also warned that the loss of scanning functionality could have more serious consequences than malfunctions involving traditional ultrasound devices because Lumify is frequently used for point-of-care diagnosis, emergency triage, and treatment decisions.

The recall does not require all affected devices to be removed from healthcare facilities or the market.

Instead, Philips issued updated instructions intended to reduce the risks while the manufacturer develops corrective measures.

The FDA and Philips recommend that healthcare professionals follow these precautions:

• Use Lumify only in areas with readily accessible Wi-Fi or cellular signals unless a backup ultrasound device is immediately available.
• Maintain backup ultrasound devices or other appropriate imaging methods for patient care.
• Distribute the updated safety instructions to healthcare professionals who operate affected devices.
• Post the manufacturer’s safety notice near affected units so clinicians can review the precautions.

Philips is developing a software update to correct unexpected registration problems and is evaluating the unstable cable connection to determine an appropriate solution.

The recall remains an important patient safety concern because a loss of ultrasound functionality during emergency care could lead to serious injuries or death, depending on the patient’s condition and the availability of alternative equipment.

Philips Lumify Ultrasound Recall Timeline

The Philips Lumify recall followed reports of medical device malfunctions and regulatory warnings about the potential consequences of interrupted diagnostic imaging.

The following timeline outlines the principal developments:

• September 24, 2026: Philips initiated a corrective action and sent updated safety instructions to affected customers, warning about unexpected transducer re-registration and unstable USB connections.
• September 29, 2026: Philips’ reported totals included four deaths and eight serious injuries associated with Lumify system unavailability.
• October 9, 2026: The FDA issued an Early Alert concerning the Philips ultrasound issues and the potential for serious patient harm.
• October 16, 2026: The FDA posted recall number Z-0152-2027 in its medical device recall database.
• October 19, 2026: The FDA updated its public communication to confirm the Class I recall classification.

Philips also announced steps to strengthen patient safety following the recall.

According to an October 2026 report from AuntMinnie, a Philips spokesperson stated that the company’s ultrasound business had established a dedicated task force to urgently address the situation.

The company said the task force would provide customized advice and support customers affected by the recall.

Philips has reported four deaths and eight serious injuries associated with the Lumify ultrasound system being unavailable or malfunctioning during medical care.

These figures include reports received since the device’s introduction in 2015.

They do not mean that all twelve incidents occurred in 2026 or that investigators have conclusively determined the device caused each patient’s injuries.

However, individual adverse-event reports describe situations in which medical professionals encountered Lumify system failures during critical procedures.

The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database includes reports of malfunctions during cardiopulmonary resuscitation, extracorporeal membrane oxygenation (ECMO), and emergency treatment of severe cardiac conditions.

Several incidents illustrate the reported risks.

October 2025: Death Reported During Emergency ECMO Treatment

An FDA adverse-event report involving an October 9, 2025, incident describes a Lumify ultrasound system that was unavailable during an emergency ECMO procedure because its transducer was not registered.

The incident was reported as resulting in a patient death.

During a subsequent investigation, Philips engineers determined that reduced mechanical retention at the transducer’s USB-C connector could cause the system to intermittently fail to recognize the transducer’s firmware version.

This could trigger an unexpected re-registration prompt.

The report identifies a potential technical mechanism for the malfunction, but the available clinical information does not independently establish that the malfunction caused the patient’s death.

April 2023: Fatal Incident During Cardiopulmonary Resuscitation

Another FDA report describes a malfunction during CPR on April 16, 2023.

The Lumify system reportedly generated an error code that prevented its use during the emergency procedure. Medical professionals exchanged the system and completed the procedure, but the patient died.

Philips investigated the reported problem and identified a possible connection between reduced USB-C connector retention and unexpected re-registration.

The report does not conclusively establish whether the device caused or contributed to the fatal outcome.

February 2023: Ultrasound Failure During Cardiac Tamponade Treatment

An additional FDA adverse-event report from February 1, 2023 describes a 54-year-old patient undergoing emergency treatment for cardiac tamponade, a condition in which fluid or blood around the heart interferes with normal cardiac function.

Medical professionals were using Lumify to guide a procedure intended to drain fluid from around the heart when the device’s cable connection reportedly became intermittent.

The medical team obtained a second ultrasound system, resulting in an interruption estimated at several minutes.

Although clinicians eventually drained the accumulated fluid and briefly restored spontaneous circulation, the patient died.

Philips’ subsequent investigation concluded that the malfunction did not cause or contribute to the death. The manufacturer attributed the fatal outcome to a rupture of the patient’s heart wall.

These reports demonstrate that Lumify equipment failures have been reported during life-threatening medical emergencies, while also showing why the medical cause of each injury or death requires individual investigation.

The FDA’s adverse-event database contains reported incidents, not final determinations of product liability.

Investigators must examine the patient’s medical condition, the nature of the malfunction, and whether any delay caused additional harm.

Philips Lumify ultrasound malfunctions may endanger patients by delaying the diagnostic information healthcare professionals need to make immediate treatment decisions.

Portable ultrasound imaging is widely used in emergency medicine because clinicians can assess internal structures, identify certain life-threatening conditions, and guide procedures without transporting unstable patients to a separate imaging department.

In many situations, the diagnostic capabilities of point-of-care ultrasound support rapid diagnosis and treatment.

A sudden system failure may interrupt this process when medical professionals have limited time to respond.

Potential consequences of delayed or unavailable ultrasound imaging include:

• Delayed diagnosis of internal bleeding: Ultrasound examinations may help identify fluid in the abdomen or around the heart following traumatic injuries. Equipment failures may postpone decisions about further testing or emergency intervention.
• Interrupted cardiac emergency treatment: Clinicians may use ultrasound to evaluate cardiac tamponade, assess cardiac activity, or guide urgent procedures. Loss of imaging may delay necessary treatment.
• Complications during resuscitation: Ultrasound can provide information during cardiac arrest management. Malfunctions may interrupt assessments or procedures that depend on real-time imaging.
• Delayed treatment in pre-hospital settings: Patients receiving emergency treatment in ambulances, aircraft, or field settings may face additional delays when cellular signal access is unavailable and replacement equipment cannot be obtained quickly.
• Worsening of existing medical conditions: In some circumstances, delayed diagnosis or treatment may contribute to prolonged oxygen deprivation, additional organ damage, permanent disability, or death.

These are potential consequences of interrupted medical care, not injuries confirmed in every Philips Lumify adverse-event report.

The central concern is that the Lumify system may stop functioning when ultrasound imaging is needed to evaluate or treat a critically ill patient.

For example, if clinicians urgently need to examine a patient’s heart but the Lumify app unexpectedly requires re-registration, the interruption may prevent them from obtaining necessary images.

The same problem may occur when an unstable connection between the transducer and mobile device disrupts continuous function during an examination.

A delay does not automatically mean the medical device caused an injury.

Establishing liability generally requires evidence that the malfunction contributed to additional harm rather than merely occurring during an already life-threatening emergency.

Patients who suffered serious injuries after a Philips Lumify ultrasound malfunction delayed diagnosis or treatment may qualify for a product liability lawsuit.

Surviving family members may also have potential wrongful death claims when evidence establishes that a defective ultrasound system caused or contributed to a patient’s death.

The October 2026 Class I recall provides grounds for investigating affected devices, but a recall alone does not establish that every patient who received treatment involving Lumify has a valid legal claim.

Potential Philips Lumify lawsuit claimants may include individuals who experienced the following circumstances:

• A Lumify ultrasound stopped functioning during an emergency medical examination or procedure.
• The Lumify app unexpectedly required re-registration, preventing clinicians from scanning while Wi-Fi or cellular service was unavailable.
• An unstable transducer connection interrupted diagnostic imaging during critical treatment.
• A healthcare professional had to obtain another ultrasound device because the original system could not perform the required examination.
• A patient suffered serious additional injuries after a documented delay in necessary diagnosis or treatment.
• A patient died following an equipment malfunction that may have contributed to delayed emergency medical intervention.

An injured patient generally must establish that a legally actionable defect or other wrongful conduct caused compensable harm.

Potential claims against a medical device manufacturer may involve defective product design, inadequate warnings, or negligence, depending on the circumstances and applicable state law.

For example, an investigation may examine whether the software registration issue created an unreasonable risk during foreseeable medical use or whether healthcare providers received adequate warning of known connectivity problems.

Liability may become more complicated when treatment delays involve both equipment problems and decisions made by healthcare professionals.

The patient’s underlying condition must also be considered. A medical emergency may be fatal even when clinicians have immediate access to functioning diagnostic equipment.

TorHoerman Law is reviewing potential claims involving serious injuries and deaths associated with Lumify equipment failures.

Whether an individual qualifies depends on the device involved, the available medical evidence, applicable law, and the circumstances surrounding the patient’s treatment.

Evidence in a Philips Lumify Ultrasound System Lawsuit

Evidence in a Philips Lumify ultrasound lawsuit may help establish when the equipment malfunctioned, how the failure affected patient care, and whether a treatment delay caused additional injury.

Patients may not know that a Philips Lumify system was used during their treatment. Hospitals and emergency medical services generally maintain records that may help identify the diagnostic equipment involved.

Relevant evidence may include:

• Medical records: Emergency department records, physician notes, imaging reports, procedure documentation, and records describing the patient’s condition before and after the equipment failure.
• Hospital and EMS incident reports: Documentation of unexpected device errors, interrupted scanning, delayed procedures, or replacement equipment.
• Device information: Model and catalogue numbers, software versions, transducer identification, and the unique device identifier associated with the affected system.
• Application and maintenance records: Available Lumify app logs, equipment service histories, software records, and documentation of previous connection problems.
• Witness statements: Accounts from medical professionals who observed the malfunction or participated in the patient’s treatment.
• Medical and technical evaluations: Expert analysis addressing the cause of the malfunction, its effect on treatment, and whether the delay contributed to the patient’s injuries.

The FDA’s recall database identifies affected Lumify Android and iOS software families and lists recall number Z-0152-2027.

This information may help determine whether equipment involved in a patient’s treatment was subject to the manufacturer’s correction.

An investigation may also require a review of when clinicians first attempted to use the device, how long scanning was unavailable, and whether another imaging system could have provided the necessary information.

Preserving equipment records and treatment documentation can be particularly important because software logs and other electronic information may not remain available indefinitely.

Potential Compensation in a Philips Lumify Ultrasound Lawsuit

Patients who establish that a defective Philips Lumify ultrasound system caused additional injuries may be entitled to compensation for financial losses and other legally recognized damages.

The amount and type of compensation depend on the severity of the injury, the role of the alleged malfunction, and the laws governing the claim.

Potential damages may include:

• Medical expenses: Costs of additional emergency treatment, hospitalization, surgery, medications, and follow-up medical care related to the injury.
• Future medical treatment: Expenses associated with rehabilitation, ongoing treatment, assistive equipment, and long-term care.
• Lost income: Wages or employment benefits lost because of the injury and, when applicable, reduced future earning capacity.
• Pain and suffering: Physical pain, emotional distress, and other non-economic losses recognized under applicable law.
• Permanent disability: Compensation for lasting physical limitations and loss of independence when supported by the evidence.
• Wrongful death damages: Funeral expenses, lost financial support, and other losses recoverable by eligible surviving family members under state law.

TorHoerman Law is investigating potential lawsuits involving patients who suffered serious injuries or died after Philips Lumify ultrasound malfunctions allegedly interrupted necessary medical care.

The FDA’s Class I recall, reports of equipment failures during emergency procedures, and documented concerns about ultrasound availability raise questions about whether affected patients and their families may have grounds for legal action.

Our law firm has experience handling complex product liability litigation involving allegedly defective medical products and representing individuals and families pursuing claims against major corporations.

A Philips Lumify lawsuit investigation may involve medical records, device information, manufacturer safety notices, and expert evaluations to determine whether a malfunction caused additional harm.

Patients and families should not assume that an equipment failure establishes liability, but they may have legal options when evidence shows that a defective medical device contributed to a serious injury or death.

If you or a loved one suffered serious complications following a Philips Lumify ultrasound malfunction, contact TorHoerman Law for a free consultation.

Our legal team can review the circumstances of your case and discuss whether you may qualify for a claim.

TorHoerman Law handles qualifying injury cases on a contingency fee basis, meaning clients generally do not pay upfront attorney fees, subject to the terms of the representation agreement.

Use the chat feature on this page to request a free case evaluation.